## We claim:

- 1. A method of treatment of obstructive respiratory diseases by inhalative administration of a pharmaceutically suitable salt of the enantiomerically pure ester (3R,2'R)-3
  [cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium in an effective amount to a patient in need thereof.
- 2. The method according to claim 1, wherein the pharmaceutically suitable salt is selected from the group consisting of fluoride, chloride, bromide and iodide.
- 3. The method according to claim 1, wherein the (3R,2'R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium has an enantiomeric purity of minimum 96% enantiomeric excess.
- 4. The method according to claim 1, wherein the (3R,2'R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium has an enantiomeric purity of minimum 97% enantiomeric excess.
- 5. The method according to claim 1, wherein the (3R,2'R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium has an enantiomeric purity of minimum 98% enantiomeric excess.

- 6. The method according to claim 1, wherein the (3R,2'R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of an aerosol formulation.
- 7. The method according to claim 1, wherein the (3R,2'R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of a dry powder formulation.
- 8. The method according to claim 1, wherein the obstructive respiratory disease is selected from the group consisting of bronchial asthma and chronic bronchitis.
- 9. The method according to claim 2, wherein the (3R,2'R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of an aerosol formulation.
- 10. The method according to claim 2, wherein the (3R,2'R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of a dry powder formulation.
- 11. The method according to claim 2, wherein the obstructive respiratory disease is selected from the group consisting of bronchial asthma and chronic bronchitis.

- 12. A method of treatment of obstructive respiratory diseases by inhalative administration of a pharmaceutically suitable salt of the enantiomerically pure ester (3S,2'R)-3
  [cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium in an effective amount to a patient in need thereof.
- 13. The method according to claim 12, wherein the pharmaceutically suitable salt is selected from the group consisting of fluoride, chloride, bromide and iodide.
- 14. The method according to claim 12, wherein the (3S,2'R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium has an enantiomeric purity of minimum 96% enantiomeric excess.
- 15. The method according to claim 12, wherein the (3S,2'R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium has an enantiomeric purity of minimum 97% enantiomeric excess.
- 16. The method according to claim 12, wherein the (3S,2'R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium has an enantiomeric purity of minimum 98% enantiomeric excess.
- 17. The method according to claim 12, wherein the (3S,2'R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of an aerosol formulation.

- 18. The method according to claim 12, wherein the (3S,2'R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of a dry powder formulation.
- 19. The method according to claim 12, wherein the obstructive respiratory disease is selected from the group consisting of bronchial asthma and chronic bronchitis.
- 20. The method according to claim 13, wherein the (3S,2'R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of an aerosol formulation.
- 21. The method according to claim 13, wherein the (3S,2'R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium salt is administered in the form of a dry powder formulation.
- 22. The method according to claim 13, wherein the obstructive respiratory disease is selected from the group consisting of bronchial asthma and chronic bronchitis.
- 23. A method of treatment of spasms of smooth muscles by administration of a pharmaceutically suitable salt of an enantiomerically pure ester selected from the group consisting of
- (3R,2'R) -3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium, ((3S,2'R)-)-3-

[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium, (3R,2'R)-3[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium, and (3S,2'R)--3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium in an effective amount to a patient in need thereof.

- 24. The method according to claim 23, wherein the pharmaceutically suitable salt is selected from the group consisting of fluoride, chloride, bromide and iodide.
- 25. The method according to claim 23, wherein said ester has an enantiomeric purity of minimum 96% enantiomeric excess.
- 26. The method according to claim 23, wherein said ester has an enantiomeric purity of minimum 97% enantiomeric excess.
- 27. The method according to claim 23, wherein said ester has an enantiomeric purity of minimum 98% enantiomeric excess.
- 28. The method according to claim 23, wherein said ester is (3R,2'R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium.

- 29. The method according to claim 23, wherein said ester is (3S,2'R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium.
- 30. The method according to claim 23, wherein said ester is (3R,2'R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium.
- 31. The method according to claim 23, wherein said ester is (3S,2'R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium.
- 32. The method according to claim 23, wherein said salt is administered by inhalation.
- 33. The method according to claim 23, wherein said salt is administered by inhalation of an aerosol formulation.
- 34. The method according to claim 23, wherein said salt is administered by inhalation of a dry powder formulation.
- 35. The method according to claim 24, wherein said salt is administered by inhalation of an aerosol formulation.
- 36. The method according to claim 24, wherein said salt is administered by inhalation of a dry powder formulation.